Results Highlights

Highlights: FY2016  Results (As of May 9, 2017)

Posted record-high profit due partly to a decrease in tax expense following a decision to withdraw from home healthcare business in the U.S.

  • Net sales: Declined, owing to
    • Impact of optimizing our production configuration associated with restructuring initiatives mainly in the resin business, in addition to the stronger yen in the first half of FY 16, although sales were generally steady across all businesses on the whole
  • Operating income and Ordinary income: Declined owing to
    • New drug licensing costs and the impact of foreign exchange movements, despite efforts to steadily improve profitability by driving growth in existing businesses and executing restructuring initiatives
  • Profit attributable to owners of parent: Up sharply, owing to
    • A decrease in tax expense exceeding extraordinary losses

In the fiscal year 2016, ending March 31, 2017, consolidated net sales for amounted to 741.3 billion yen, down -49.5 billion yen compared with 790.7 billion yen for the fiscal 2015. Operating income for the fiscal 2016 were 56.5 billion yen, down -10.6 billion yen compared with 67.1 billion yen for the fiscal 2015. Ordinary income for the fiscal 2016 amounted to 55.9 billion yen, down -4.4 billion yen compared with 60.3billion yen for the fiscal 2015. Profit attributable to
owners of parent of 50.1 billion yen for the fiscal 2016 increased +19.0 billion yen compared with net loss of 31.1billion yen in the fiscal 2015.

Total assets as of March 31, 2017, amounted to 964.1 billion yen, increase of +140.6 billion yen from the end of fiscal
2015(823.4 billion yen). Shareholders´ equity was 338.4 billion yen, increase of +38.3 billion yen compared with
300.1 billion yen. Interest-bearing debt was increased +72.9 billion yen, from 376.2 billion yen at the end of fiscal
2015 to 303.3 billion yen.

* Profit attributable to owners of parent